Lipocine Statistics

Total Valuation

Lipocine has a market cap or net worth of $20.28 million. The enterprise value is -$4.45 million.

Market Cap	20.28M
Enterprise Value	-4.45M

Important Dates

The next estimated earnings date is Tuesday, August 4, 2026, before market open.

Earnings Date	Aug 4, 2026
Ex-Dividend Date	n/a

Share Statistics

Lipocine has 8.24 million shares outstanding. The number of shares has increased by 8.67% in one year.

Current Share Class	8.24M
Shares Outstanding	8.24M
Shares Change (YoY)	+8.67%
Shares Change (QoQ)	+19.61%
Owned by Insiders (%)	4.53%
Owned by Institutions (%)	26.31%
Float	6.91M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	10.13
Forward PS	30.87
PB Ratio	0.81
P/TBV Ratio	0.89
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 9.99

Current Ratio	9.99
Quick Ratio	9.87
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -54.41% and return on invested capital (ROIC) is -36.08%.

Return on Equity (ROE)	-54.41%
Return on Assets (ROA)	-33.07%
Return on Invested Capital (ROIC)	-36.08%
Return on Capital Employed (ROCE)	-53.13%
Weighted Average Cost of Capital (WACC)	6.80%
Revenue Per Employee	$143,015
Profits Per Employee	-$816,752
Employee Count	14
Asset Turnover	0.09
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -23.84% in the last 52 weeks. The beta is 0.46, so Lipocine's price volatility has been lower than the market average.

Beta (5Y)	0.46
52-Week Price Change	-23.84%
50-Day Moving Average	2.30
200-Day Moving Average	4.67
Relative Strength Index (RSI)	54.65
Average Volume (20 Days)	112,883

Short Selling Information

The latest short interest is 90,238, so 1.09% of the outstanding shares have been sold short.

Short Interest	90,238
Short Previous Month	102,133
Short % of Shares Out	1.09%
Short % of Float	1.31%
Short Ratio (days to cover)	0.89

Income Statement

In the last 12 months, Lipocine had revenue of $2.00 million and -$11.43 million in losses. Loss per share was -$1.97.

Revenue	2.00M
Gross Profit	2.00M
Operating Income	-12.13M
Pretax Income	-11.43M
Net Income	-11.43M
EBITDA	-12.07M
EBIT	-12.13M
Loss Per Share	-$1.97

Full Income Statement

Balance Sheet

The company has $24.73 million in cash and n/a in debt, giving a net cash position of $24.73 million or $3.00 per share.

Cash & Cash Equivalents	24.73M
Total Debt	n/a
Net Cash	24.73M
Net Cash Per Share	$3.00
Equity (Book Value)	22.83M
Book Value Per Share	3.05
Working Capital	22.72M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-10.05M
Capital Expenditures	n/a
Depreciation & Amortization	60,026
Net Borrowing	n/a
Free Cash Flow	-10.05M
FCF Per Share	-$1.22

Full Cash Flow Statement

Margins

Gross Margin	100.00%
Operating Margin	-605.86%
Pretax Margin	-571.10%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Lipocine does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-8.67%
Shareholder Yield	-8.67%
Earnings Yield	-56.38%
FCF Yield	-49.55%

Analyst Forecast

The average price target for Lipocine is $6.00, which is 143.90% higher than the current price. The consensus rating is "Buy".

Price Target	$6.00
Price Target Difference	143.90%
Analyst Consensus	Buy
Analyst Count	2
Revenue Growth Forecast (3Y)	-15.33%
EPS Growth Forecast (3Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on May 12, 2023. It was a reverse split with a ratio of 1:17.

Last Split Date	May 12, 2023
Split Type	Reverse
Split Ratio	1:17

Scores

Lipocine has an Altman Z-Score of -6.07 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-6.07
Piotroski F-Score	1